Top Suppliers:I want be here

  • DC Chemicals Limited
  • China
  • Product Name: NSC 36333
  • Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

1837-57-6

1837-57-6 structure
1837-57-6 structure

Name 6,9-diamino-2-ethoxyacridine lactate
Synonyms Ethacridine Lactate
RIVANOL
rivinol
2-Hydroxypropanoic acid - 7-ethoxy-3,9-acridinediamine (1:1)
7-ethoxy-acridine-3,9-diyldiamine,DL lactate
rimaon
MFCD00013149
2-ethoxy-6,9-diaminoacridine lactate
UNII:7T7T2I9823
Propanoic acid, 2-hydroxy-, compd. with 7-ethoxy-3,9-acridinediamine (1:1)
flavitrol
EINECS 217-408-1
ETHODIN
TCMDC-123983
ACRYNOL
metifex
2-Hydroxypropanoic acid - 7-ethoxyacridine-3,9-diamine (1:1)
Vucine
ACRINOL
Ethacridine (lactate)
Description Ethacridine lactate is a poly(ADP-ribose) glycohydrolase (PARG) inhibitor.
Related Catalog
Target

PARG[1]

In Vitro Ethacridine lactate is effective against mostly gram-positive species like Streptococci and Staphylococci and ineffective against gram-negative(P seudomonas aeruginosa)[1]. Ethacridine Lactate is a safe abortifacient with about 80% success and hardly any side effects[2].
In Vivo The incidence of retained placenta is 16%. The extra-amniotic injection is a technically simple procedure and can be carried out even between 13-15 weeks of pregnancy when intraamniotic injection is difficult. Its bactericidal properties minimize the danger of post-abortal infection. It can be used in certain medical conditions like hypertension, bronchial asthma where hypertonic saline and prostaglandin are contraindi-cated[2]. Ethacridine lactate performs better than other instillation abortion methods and it is a safe and effective method. Ethacridine lactate induces successful abortion in 92.8% of cases which is much higher than that found in the literature (about 82%). Abortion failure occurrs in the other 4 cases because of transverse lie of fetus, cervical dystocia, and uterine inertia[2].
References

[1]. Rotin LE, et al. Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells. Haematologica. 2016 Nov;101(11):e449-e453.

[2]. Purandare VN, et al. The place of ethacridine lactate for mid-trimester M.T.P. (Multicentric study). J Postgrad Med. 1977 Apr;23(2):77-83.

[3]. Gupta S, et al. Ethacridine lactate -- a safe and effective drug for termination of pregnancy. Indian J Matern Child Health. 1993;4(2):59-61.

Boiling Point 270 °C(lit.)
Melting Point 62-67 °C(lit.)
Molecular Formula C18H21N3O4
Molecular Weight 343.377
Flash Point 143 °C
Exact Mass 343.153198
PSA 131.69000
LogP 3.56530
Vapour Pressure 4.72E-11mmHg at 25°C
Water Solubility soluble
Name: 6 9-Diamino-2-Ethoxyacridine Lactate 95% (Titr.) Material Safety Data Sheet
Synonym: 6,9-Acridinediamine, 2-Ethoxy-, 2-Hydroxypropanote; Acrinol; Ethodin
CAS: 1837-57-6
Section 1 - Chemical Product MSDS Name:6 9-Diamino-2-Ethoxyacridine Lactate 95% (Titr.) Material Safety Data Sheet
Synonym:6,9-Acridinediamine, 2-Ethoxy-, 2-Hydroxypropanote; Acrinol; Ethodin

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
1837-57-6 Propanoic acid, 2-hydroxy-, compd. wit 95 217-408-1
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1837-57-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C18H21N3O4.H2O
Molecular Weight: 361.39

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1837-57-6: OD4725000 LD50/LC50:
Not available.
Carcinogenicity:
Propanoic acid, 2-hydroxy-, compd. with7-ethoxy-3,9-acridine - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 1837-57-6: No information available.
Canada
CAS# 1837-57-6 is listed on Canada's NDSL List.
CAS# 1837-57-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1837-57-6 is listed on the TSCA inventory.


SECTION 16 - ADDITIONAL INFORMATION
N/A

CHEMICAL IDENTIFICATION

RTECS NUMBER :
OD4725000
CAS REGISTRY NUMBER :
1837-57-6
LAST UPDATED :
199806
DATA ITEMS CITED :
11
MOLECULAR FORMULA :
C15-H15-N3-O.C3-H6-O3
MOLECULAR WEIGHT :
343.42
WISWESSER LINE NOTATION :
T C666 BNJ EZ IZ LO2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
120 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
20 mg/kg
TOXIC EFFECTS :
Vascular - shock
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
48 gm/kg/30D-C
TOXIC EFFECTS :
Endocrine - other changes Endocrine - changes in thymus weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
420 mg/kg/21D-I
TOXIC EFFECTS :
Liver - changes in liver weight Endocrine - changes in spleen weight

MUTATION DATA

TYPE OF TEST :
Mutation in microorganisms
TEST SYSTEM :
Microorganism - not otherwise specified
DOSE/DURATION :
250 mg/L
REFERENCE :
PNASA6 Proceedings of the National Academy of Sciences of the United States of America. (National Academy of Sciences, Printing & Pub. Office, 2101 Constitution Ave., Washington, DC 20418) V.1- 1915- Volume(issue)/page/year: 56,500,1966 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5763 No. of Facilities: 23 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 23 (estimated)
HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%